RedHill Biopharma (RDHL) Revenue (2012 - 2023)

RedHill Biopharma (RDHL) has 11 years of Revenue data on file, last reported at $1.8 million in Q2 2023.

• Revenue for Q2 2023 came in at $1.8 million, down 90.21% year-over-year; the trailing twelve-month figure through Jun 2023 was $35.7 million (down 52.42% YoY), and the FY2025 annual result was $286000.0, down 96.44% from the prior year.
• Revenue slipped to $1.8 million in Q2 2023 per RDHL's latest filing, from $3.6 million in the prior quarter.
• Over five years, Revenue peaked at $22.1 million in Q4 2021 and troughed at $1.1 million in Q1 2020.
• A 5-year average of $12.4 million and a median of $15.3 million in 2022 frame the typical range for Revenue.
• The sharpest annual moves came in 2021 and 2023: Revenue jumped 1848.39% in 2021, then tumbled 90.21% in 2023.
• A 5-year view of Revenue shows it stood at $1.6 million in 2019, then surged by 1249.75% to $21.5 million in 2020, then rose by 2.84% to $22.1 million in 2021, then slumped by 42.01% to $12.8 million in 2022, then plunged by 85.97% to $1.8 million in 2023.
• Business Quant data shows RDHL's Revenue at $1.8 million in Q2 2023, $3.6 million in Q1 2023, and $12.8 million in Q4 2022.